← Leaderboards
Jay W Heinecke
University Of Washington
$34,087,651
Attributed
$36,641,942
Total exposure
32
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,641,942 · 32
By mechanism
R01$18,512,289 · 11
P01$14,020,468 · 10
DP3$1,599,819 · 1
P30$1,533,424 · 3
P41$975,942 · 7
Top collaborators
- Karin E. Bornfeldt5 shared
- Tomas Vaisar5 shared
Most similar at University Of Washington
Same institution · by research overlap
- Jan Christian Lood$4,492,233
- Kevin D. O'Brien$6,249,245
- Alan Chait$20,398,633
- Peter S Rabinovitch$49,936,459
- Renee C Leboeuf$13,817,725
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsAtherosclerosisMacrophageHigh Density LipoproteinsLipidsPathway InteractionsInflammationCholesterolCardiovascular Disorder RiskOxidationCardiovascular DiseasesMouse ModelArteriesPropertyParticleProgramsPlasmaApolipoprotein A-IIn VivoComplementMolecularHigh Density Lipoprotein CholesterolClinical ResearchDiabetes Mellitus
Grant awards (118)
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes$808,164
R01 · FY2025 · HL · contact PI
Cardioprotection by extra-small HDL particles$543,880
P01 · FY2025 · HL · contact PI
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes$823,854
R01 · FY2024 · HL · contact PI
Cardioprotection by extra-small HDL particles$486,499
P01 · FY2024 · HL · contact PI
Project 4: Lipoproteins and CVD risk in diabetes$435,175
P01 · FY2024 · HL · contact PI
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes$823,854
R01 · FY2023 · HL · contact PI
Structural basis for cardioprotective HDL$691,232
R01 · FY2023 · HL · contact PI
Cardioprotection by extra-small HDL particles$514,713
P01 · FY2023 · HL · contact PI
Project 4: Lipoproteins and CVD risk in diabetes$443,209
P01 · FY2023 · HL · contact PI
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes$862,314
R01 · FY2022 · HL · contact PI
Structural basis for cardioprotective HDL$691,232
R01 · FY2022 · HL · contact PI
Project 4: Lipoproteins and CVD risk in diabetes$434,723
P01 · FY2022 · HL · contact PI
Structural basis for cardioprotective HDL$691,232
R01 · FY2021 · HL · contact PI
Project 4: Lipoproteins and CVD risk in diabetes$433,976
P01 · FY2021 · HL · contact PI
Structural basis for cardioprotective HDL$688,354
R01 · FY2020 · HL · contact PI
Project 4: Lipoproteins and CVD risk in diabetes$455,928
P01 · FY2020 · HL · contact PI
Project 3 - HDL Structure/Function in LCAT Deficient Humans$262,515
P01 · FY2020 · HL · contact PI
Quantitative and Functional Proteomics Core$132,526
P30 · FY2020 · DK · contact PI
Project 1: HDL Function and Oxidation in Diabetic Atherosclerosis$469,137
P01 · FY2019 · HL · contact PI
Project 3 - HDL Structure/Function in LCAT Deficient Humans$262,515
P01 · FY2019 · HL · contact PI
Project 1: HDL Function and Oxidation in Diabetic Atherosclerosis$481,285
P01 · FY2018 · HL · contact PI
Project 3 - HDL Structure/Function in LCAT Deficient Humans$262,515
P01 · FY2018 · HL · contact PI
Quantitative and Functional Proteomics Core$132,150
P30 · FY2018 · DK · contact PI
Project 1: HDL Function and Oxidation in Diabetic Atherosclerosis$481,262
P01 · FY2017 · HL · contact PI
Project 3 - HDL Structure/Function in LCAT Deficient Humans$262,515
P01 · FY2017 · HL · contact PI
Core F: Quantitative and Functional Proteomics Core$217,889
P30 · FY2017 · DK · contact PI
Project 1: HDL Function and Oxidation in Diabetic Atherosclerosis$461,481
P01 · FY2016 · HL · contact PI
Quantitative Assessment of HDL Function$435,000
R01 · FY2016 · HL · contact PI
Project 3 - HDL Structure/Function in LCAT Deficient Humans$283,014
P01 · FY2016 · HL · contact PI
Core F: Quantitative and Functional Proteomics Core$217,891
P30 · FY2016 · DK · contact PI
APOC3, HDL Function and Cardiovascular Complications of T1DM$1,599,819
DP3 · FY2015 · DK
Project 1: HDL Function and Oxidation in Diabetic Atherosclerosis$461,481
P01 · FY2015 · HL · contact PI
Quantitative Assessment of HDL Function$428,475
R01 · FY2015 · HL · contact PI
Cardioprotective Mechanisms of HDL$428,475
R01 · FY2015 · HL · contact PI
Core F: Quantitative and Functional Proteomics Core$217,830
P30 · FY2015 · DK · contact PI
Quantitative Assessment of HDL Function$426,300
R01 · FY2014 · HL · contact PI
Cardioprotective Mechanisms of HDL$426,300
R01 · FY2014 · HL · contact PI
Core F: Quantitative and Functional Proteomics Core$217,933
P30 · FY2014 · DK · contact PI
Cardioprotective Mechanisms of HDL$413,525
R01 · FY2013 · HL · contact PI
Quantitative Assessment of HDL Function$412,930
R01 · FY2013 · HL · contact PI
Core F: Quantitative and Functional Proteomics Core$207,205
P30 · FY2013 · DK · contact PI
Cardioprotective Mechanisms of HDL$431,875
R01 · FY2012 · HL · contact PI
Quantitative Assessment of HDL Function$431,250
R01 · FY2012 · HL · contact PI
Molecular Mechanisms of Atherogenesis in Diabetes$415,359
P01 · FY2012 · HL · contact PI
Core C Mass Spectrometry Core$149,342
P01 · FY2012 · HL · contact PI
Molecular Mechanisms of Atherogenesis in Diabetes$415,359
P01 · FY2011 · HL · contact PI
Molecular Mechanisms for Dysfunctional High Density Lipoprotein (HDL)$380,126
R01 · FY2011 · HL · contact PI
Core C Mass Spectrometry Core$149,344
P01 · FY2011 · HL · contact PI
Molecular Mechanisms of Atherogenesis in Diabetes$415,359
P01 · FY2010 · HL · contact PI
Molecular Mechanisms for Dysfunctional High Density Lipoprotein (HDL)$380,126
R01 · FY2010 · HL · contact PI
Atherogenic Effects of Oxidized High Density Lipoproteins$378,690
R01 · FY2010 · HL · contact PI
Core C Mass Spectrometry Core$149,344
P01 · FY2010 · HL · contact PI
Pathways of Oxidation of HDL by Macrophages$465,921
P01 · FY2009 · HL · contact PI
Molecular Mechanisms of Atherogenesis in Diabetes$415,359
P01 · FY2009 · HL · contact PI
Molecular Mechanisms for Dysfunctional High Density Lipoprotein (HDL)$380,126
R01 · FY2009 · HL · contact PI
Atherogenic Effects of Oxidized High Density Lipoproteins$378,690
R01 · FY2009 · HL · contact PI
Protein Chemistry Core$154,032
P01 · FY2009 · HL · contact PI
Core C Mass Spectrometry Core$149,344
P01 · FY2009 · HL · contact PI
Pathways of Oxidation of HDL by Macrophages$445,671
P01 · FY2008 · HL · contact PI
Molecular Mechanisms of Atherogenesis in Diabetes$415,354
P01 · FY2008 · HL · contact PI
Molecular Mechanisms for Dysfunctional High Density Lipoprotein (HDL)$380,126
R01 · FY2008 · HL · contact PI
Macrophage-Derived Oxidants in Atherogenesis$369,790
R01 · FY2008 · HL · contact PI
Core C Mass Spectrometry Core$149,339
P01 · FY2008 · HL · contact PI
Protein Chemistry Core$147,167
P01 · FY2008 · HL · contact PI
Pathways of Oxidation of HDL by Macrophages$441,898
P01 · FY2007 · HL · contact PI
Molecular Mechanisms for Dysfunctional High Density Lipoprotein (HDL)$394,126
R01 · FY2007 · HL · contact PI
Macrophage-Derived Oxidants in Atherogenesis$369,790
R01 · FY2007 · HL · contact PI
Protein Chemistry Core$145,761
P01 · FY2007 · HL · contact PI
Pathways of Oxidation of HDL by Macrophages$410,857
P01 · FY2006 · HL · contact PI
Macrophage-Derived Oxidants in Atherogenesis$379,818
R01 · FY2006 · HL · contact PI
Pathways for the Inflammatory Damage of Biomolecules$333,083
R01 · FY2006 · AG · contact PI
Protein Chemistry Core$135,459
P01 · FY2006 · HL · contact PI
Pathways of Oxidation of HDL by Macrophages$398,893
P01 · FY2005 · HL
Macrophage-Derived Oxidants in Atherogenesis$388,750
R01 · FY2005 · HL
Pathways for the Inflammatory Damage of Biomolecules$341,100
R01 · FY2005 · AG
Protein Chemistry Core$131,513
P01 · FY2005 · HL
NEURONAL EXPRESSIONOF MYCLO IS INCREASED IN ALZHEIMER'S DISEASE$649
P41 · FY2005 · RR
CT OF VITAMIN E IN CORONARY ARTERY DISEASE$649
P41 · FY2005 · RR
OXIDATIVE STRESS NEW APPROACHES TO DIAGNOSIS &PROGNOSIS IN ATHEROSCLEROSIS$649
P41 · FY2005 · RR
TYROSYL RADICAL PRODUCTION BY MYELOPEROXIDASE PHAGOCYTE PATHWAY$649
P41 · FY2005 · RR
Pathways for the Inflammatory Damage of Biomolecules$341,100
R01 · FY2004 · AG
Pathways for oxidative damage of DNA by phagocytes$303,200
R01 · FY2004 · AG
TYROSYL RADICAL PRODUCTION BY MYELOPEROXIDASE PHAGOCYTE PATHWAY$804
P41 · FY2004 · RR
OXIDATIVE STRESS NEW APPROACHES TO DIAGNOSIS &PROGNOSIS IN ATHEROSCLEROSIS$804
P41 · FY2004 · RR
CT OF VITAMIN E IN CORONARY ARTERY DISEASE$804
P41 · FY2004 · RR
OXIDIZED AMINO ACIDS CULPRITS IN HUMAN ATHEROSCLEROSIS$804
P41 · FY2004 · RR
Pathways for the Inflammatory Damage of Biomolecules$341,100
R01 · FY2003 · AG
Pathways for oxidative damage of DNA by phagocytes$303,200
R01 · FY2003 · AG
Pathways for oxidative damage of DNA by phagocytes$308,000
R01 · FY2002 · AG
Pathways for the Inflammatory Damage of Biomolecules$306,000
R01 · FY2002 · AG
REACTIVE ALDEHYDES AND CARDIOVASCULAR AGING$274,293
R01 · FY2002 · AG
OXIDATIVE MECHANISMS OF AAA FORMATION (COLLABORATIVE R01$227,400
R01 · FY2002 · HL
PATHWAYS FOR OXIDATION OF LOW DENSITY LIPOPROTEIN BY MYELOPEROXIDASE$157,506
P41 · FY2002 · RR
DETECTING OXIDATIVE MODIFICATION OF BIOMOLECULES IN VIVO$157,506
P41 · FY2002 · RR
REACTIVE ALDEHYDES DERIVED FROM REDUCING SUGARS$157,506
P41 · FY2002 · RR
MOLECULAR MECHANISMS OF OXIDATIVE DAMAGE IN DIABETES$130,479
P01 · FY2002 · DK
CORE--PROTEIN CHEMISTRY$130,479
P01 · FY2002 · DK
Pathways for the Inflammatory Damage of Biomolecules$38,438
R01 · FY2002 · AG
Core--Protein Chemistry$0
P01 · FY2002 · DK
CORE--BIOMOLECULAR ANALYSIS$0
P30 · FY2002 · DK
Molecular Mechanisms of Atherogenesis in Diabetes$0
P01 · FY2002 · DK
Pathways for oxidative damage of DNA by phagocytes$308,000
R01 · FY2001 · AG
REACTIVE ALDEHYDES AND CARDIOVASCULAR AGING$266,304
R01 · FY2001 · AG
OXIDATIVE MECHANISMS OF AAA FORMATION (COLLABORATIVE R01$234,000
R01 · FY2001 · HL
DETECTING OXIDATIVE MODIFICATION OF BIOMOLECULES IN VIVO$157,506
P41 · FY2001 · RR
REACTIVE ALDEHYDES DERIVED FROM REDUCING SUGARS$157,506
P41 · FY2001 · RR
PATHWAYS FOR OXIDATION OF LOW DENSITY LIPOPROTEIN BY MYELOPEROXIDASE$157,506
P41 · FY2001 · RR
CORE--PROTEIN CHEMISTRY$130,479
P01 · FY2001 · DK
MOLECULAR MECHANISMS OF OXIDATIVE DAMAGE IN DIABETES$130,479
P01 · FY2001 · DK
CORE--BIOMOLECULAR ANALYSIS$0
P30 · FY2001 · DK
REACTIVE ALDEHYDES AND CARDIOVASCULAR AGING$258,547
R01 · FY2000 · AG
OXIDATIVE MECHANISMS OF AAA FORMATION (COLLABORATIVE R01$234,000
R01 · FY2000 · HL
CORE--BIOMOLECULAR ANALYSIS$190,000
P30 · FY2000 · DK
MOLECULAR MECHANISMS OF OXIDATIVE DAMAGE IN DIABETES$181,027
P01 · FY2000 · DK
CORE--PROTEIN CHEMISTRY$181,027
P01 · FY2000 · DK
DETECTING OXIDATIVE MODIFICATION OF BIOMOLECULES IN VIVO$13,038
P41 · FY2000 · RR
PATHWAYS FOR OXIDATION OF LOW DENSITY LIPOPROTEIN BY MYELOPEROXIDASE$6,028
P41 · FY2000 · RR
REACTIVE ALDEHYDES DERIVED FROM REDUCING SUGARS$6,028
P41 · FY2000 · RR